ACE1831 Trial
Phase 1
42
about 4.7 years
18+
5 sites in FL, GA, IN +2
About this study
Researchers are testing a new treatment called ACE1831 for people with relapsed or refractory CD20-expressing B-cell malignancies. The trial will evaluate the safety, tolerability, and effectiveness of ACE1831 in adults.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ACE1831
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, obinutuzumab
infusion, injection, intravenous
Primary: Change from baseline clinical laboratory tests results, Change from baseline in ECOG status, Change from baseline in electrocardiogram (ECG) results, Change from baseline in physical examination results, Change from baseline in urinalysis results, Change from baseline in vital signs results, Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs), Maximum Tolerated Dose (MTD)
Secondary: Objective Response Rate (ORR)
Oncology